Pancreatic Cancer Research

ResearcherQueen Mary University of LondonActive in the last 2 years

Christopher Heeschen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1158-8554; OpenAlex author ID A5058816620. Sources: OpenAlex.

Their work

Papers
53 (first author 1, last author 27)
Trials
0
Grants
0
Labs led
3
Collaborators
117
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 3 papers · 2014: 3 papers · 2015: 6 papers · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 5 papers · 2020: 5 papers · 2021: 3 papers · 2022: 1 paper · 2023: 6 papers · 2024: 5 papers · 2025: 4 papers · 2026: 2 papers

Papers 50 of 53

  1. Multimodal C9-66 CAR-T cell immunotherapy improves outcome in preclinical models of pancreatic cancer. Last author DOI 10.1136/gutjnl-2025-337545↗
  2. FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-25-1001↗
  3. CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer. Last author DOI 10.1002/adhm.202500546↗
  4. Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. Last author DOI 10.1016/j.xpro.2025.103635↗
  5. Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in PDAC. Last author DOI 10.1016/j.ymthe.2025.09.004↗
  6. PPARδ Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3475↗
  7. A Self-Assembled 3D Model Demonstrates How Stiffness Educates Tumor Cell Phenotypes and Therapy Resistance in Pancreatic Cancer. Co-author DOI 10.1002/adhm.202301941↗
  8. Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis-Independent Mechanism. Last author DOI 10.1002/advs.202308990↗
  9. CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. Last author DOI 10.1016/j.xcrm.2024.101692↗
  10. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2023-330995↗
  11. Fatty acid oxidation is critical for the tumorigenic potential and chemoresistance of pancreatic cancer stem cells. Co-author DOI 10.1186/s12967-024-05598-6↗
  12. Dissecting the role of toll-like receptor 7 in pancreatic cancer. Co-author DOI 10.1002/cam4.5606↗
  13. Liquid biopsy in pancreatic cancer - Current perspective and future outlook. Last author DOI 10.1016/j.bbcan.2023.188868↗
  14. Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biopha.2022.114162↗
  15. Single-cell omics: a new perspective for early detection of pancreatic cancer? Last author DOI 10.1016/j.ejca.2023.112940↗
  16. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325564↗
  17. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. Last author DOI 10.1186/s13046-023-02883-y↗
  18. LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer. Co-author DOI 10.1186/s13046-022-02516-w↗
  19. Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Co-author DOI 10.1038/s41467-021-25921-9↗
  20. PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer Co-author DOI 10.1101/2021.11.15.468579↗
  21. Inhibition of Mitochondrial Dynamics Preferentially Targets Pancreatic Cancer Cells with Enhanced Tumorigenic and Invasive Potential. Co-author DOI 10.3390/cancers13040698↗
  22. TGF-β1 secreted by pancreatic stellate cells promotes stemness and tumourigenicity in pancreatic cancer cells through L1CAM downregulation. Co-author DOI 10.1038/s41388-020-1289-1↗
  23. Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells. Co-author DOI 10.1038/s41467-020-18954-z↗
  24. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Co-author DOI 10.3390/ijms21207437↗
  25. Correction: Alcalá, S., et al. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Int. J. Mol. Sci. 2020, 21, 7437. Co-author DOI 10.3390/ijms21239215↗
  26. Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells. Co-author DOI 10.4252/wjsc.v12.i11.1410↗
  27. Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes. Co-author DOI 10.1016/j.bbagen.2018.09.018↗
  28. Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity. Last author DOI 10.1038/s41388-019-0871-x↗
  29. Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-019-11752-2↗
  30. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1136/gutjnl-2018-316595↗
  31. The Anthrax Toxin Receptor 1 (ANTXR1) Is Enriched in Pancreatic Cancer Stem Cells Derived from Primary Tumor Cultures. Co-author DOI 10.1155/2019/1378639↗
  32. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-018-03962-x↗
  33. Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells. Co-author DOI 10.1016/j.bbagen.2017.01.035↗
  34. ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Co-author DOI 10.1038/onc.2016.459↗
  35. More challenges ahead-metabolic heterogeneity of pancreatic cancer stem cells. Co-author DOI 10.1080/23723556.2015.1105353↗
  36. DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster. Co-author DOI 10.1158/0008-5472.can-15-3268↗
  37. Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation. Last author DOI 10.1002/stem.2114↗
  38. MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Last author DOI 10.1016/j.cmet.2015.08.015↗
  39. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Last author DOI 10.1136/gutjnl-2014-308470↗
  40. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Last author DOI 10.1136/gutjnl-2014-308935↗
  41. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Last author DOI 10.1158/1078-0432.ccr-14-1399↗
  42. Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. Last author DOI 10.3791/52801↗
  43. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Last author DOI 10.1053/j.gastro.2014.08.002↗
  44. ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Co-author DOI 10.1158/0008-5472.can-14-1354↗
  45. Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Last author DOI 10.1158/1535-7163.mct-13-0948↗
  46. Stem cells & pancreatic cancer. Last author DOI 10.1016/j.pan.2012.12.003↗
  47. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. Last author DOI 10.1371/journal.pone.0066371↗
  48. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. Last author DOI 10.1371/journal.pone.0076518↗
  49. Stem cells as the root of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.yexcr.2011.11.007↗
  50. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Last author DOI 10.1158/1078-0432.ccr-11-1270↗

Closest collaborators

The 25 strongest of 117 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bruno Sáinz · 21 shared papers, 2013–2025 · strength 1.92
  2. Patricia Sancho · 15 shared papers, 2013–2025 · strength 1.60
  3. Berina Šabanović · 7 shared papers, 2023–2026 · strength 1.31
  4. Sonia Alcalá · 12 shared papers, 2011–2024 · strength 1.25
  5. Sara Maria David Trabulo · 14 shared papers, 2013–2025 · strength 1.19
  6. Quan Zheng · 7 shared papers, 2021–2025 · strength 1.14
  7. Jiajia Tang · 6 shared papers, 2021–2025 · strength 0.99
  8. Chenlei Wen · 5 shared papers, 2024–2026 · strength 0.96
  9. Yaru Zhao · 4 shared papers, 2023–2025 · strength 0.82
  10. Petra Jagušt · 6 shared papers, 2015–2025 · strength 0.78
  11. Sarah Courtois · 5 shared papers, 2021–2025 · strength 0.77
  12. Pilar Espiau-Romera · 4 shared papers, 2021–2025 · strength 0.65
  13. Aldo Scarpa · 4 shared papers, 2021–2024 · strength 0.60
  14. Ke Jiang · 3 shared papers, 2023–2026 · strength 0.59
  15. Beatriz Parejo-Alonso · 4 shared papers, 2021–2025 · strength 0.57
  16. Baiyong Shen · 3 shared papers, 2024–2025 · strength 0.55
  17. Qi Wang · 3 shared papers, 2023–2025 · strength 0.54
  18. Juan Carlos López-Gil · 4 shared papers, 2020–2024 · strength 0.51
  19. Da Fu · 3 shared papers, 2024–2025 · strength 0.50
  20. Patrick Christian Hermann · 7 shared papers, 2011–2023 · strength 0.46
  21. Miriam Roberto · 2 shared papers, 2026 · strength 0.46
  22. Rita Teresa Lawlor · 3 shared papers, 2021–2024 · strength 0.45
  23. Enza Lonardo · 7 shared papers, 2011–2022 · strength 0.44
  24. Manuel M. Hidalgo · 8 shared papers, 2011–2023 · strength 0.41
  25. Baiyong Shen · 2 shared papers, 2024–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.